您所在的位置:
作者:黄卓颍
单位:福建医科大学附属第一医院

摘要

This study aims to evaluate the long-term therapeutic efficacy and safety of AAV-mediated hfCas12Max-ATXN3 gRNA DNA editing in neonatal and adult humanized SCA3 mouse models.


Design and screen guide RNAs (gRNAs) targeting the human ATXN3 gene, and construct and package AAV vectors. Using humanized YACMJD84.2Q-C57BL/6 homozygous SCA3 mice (hereinafter referred to as 84Q/84Q mice) as the model, low-dose (neonates: 5.0×10^10 vg/mouse; adults: 2.5×10^11 vg/mouse) and high-dose (neonates: 1.0×10^11 vg/mouse; adults: 5.0×10^11 vg/mouse) AAV-hfCas12Max-ATXN3 gRNA interventions were administered via intracisternal magnal injection (ICM) during neonatal (P0-1) and adult (3 months of age) stages of the model mice. The viral distribution (copy number) in key brain regions was detected using absolute quantitative polymerase chain reaction (PCR); the frequency of ATXN3 gene insertions/deletions (indels) was assessed by next-generation sequencing (NGS); protein expression was analyzed via Western blot (WB) and immunofluorescence (IF) assays; motor function in model mice was evaluated through behavioral experiments; serum biochemical parameters and neurofilament light chain (NfL) levels were measured; and safety was evaluated via multi-organ histopathological examination.


1. In vitro screening showed that gRNA4 and gRNA11 effectively targeted the ATXN3 gene and induced significant indel effects (gRNA4: 41.41% ± 1.49%, gRNA11: 40.13% ± 0.27%).

2. In neonatal 84Q/84Q mice, the system efficiently targeted the cerebellum and brainstem, with a reduction in mutant protein expression and aggregation observed within one month (P<0.05). After 6 months, the viral vector continued to express stably in the brain, maintaining gene editing efficiency and long-term suppression of mutant protein expression. Neuroinflammation was reduced, Purkinje cell loss was rescued, and motor function was significantly improved (P<0.05).

3. In adult 84Q/84Q mice, treatment after 3 months resulted in efficient delivery and editing of both low and high doses, with a significant reduction in mutant protein expression (P<0.05). However, no significant difference was found in HMW aggregate levels. There were no significant changes in body weight, length, or width compared to the untreated group. Balance coordination and fatigue rotarod tests showed significant recovery in both the low- and high-dose groups (P<0.05), while open-field activity remained unchanged. Histological analysis revealed reduced astrocyte proliferation, increased Purkinje cell survival, and restored NfL levels (P<0.05).

4. In adult wild-type mice, high-dose treatment did not induce motor dysfunction or abnormal changes in ALT, AST, BUN, or histopathological structure in the brain, liver, or kidney.


The AAV-hfCas12Max-ATXN3 gRNA gene editing system provides a durable, specific, and safe therapeutic strategy that significantly improves motor function and delays neurodegenerative changes in the SCA3 mouse model.


关键词:Spinocerebellar Ataxia Type 3 CRISPR/hfCas12Max Adeno-associated virus; Neurodegenerative disease; Gene therapy
来源:中华医学会第四届罕见病学术年会暨2026中华医学会罕见病分会中青年学术会议

相关会议

更多
淋髓思辨系列会(第一期)
2026-11-30
“医”路携手,“药”有作为一基层抗感染系列学术研讨会(3)
2026-11-30
北京

相关直播

更多
第八届上海国际癌症大会
2026-06-03
上海静安英迪格酒店
观看回放
产前咨询
2026-09-01
产前咨询
观看回放
阜外肺血管病区教学培训:第三类PH的影像与血流动力学映射关系的探索与思考
2026-11-18
阜外肺血管病区教学培训
观看回放

最新视频

更多
消化内镜学习实践与创新
杨云生
中国人民解放军总医院第一医学中心
分子感知电子胶囊
王汉杰
天津大学医学部生命科学学院
早发性结直肠癌的诊治与防控
刘晓峰
中国人民解放军联勤保障部队第九六〇医院
间充质干细胞内镜下注射治疗慢性放射性直肠损伤的探索
宣佶
东总秦淮医疗区